参考文献/References:
[1] Loncar G,Fülster S,von Haehling S,et al.Metabolism and the heart: an overview of muscle, fat,and bone metabolism in heart failure[J].Int J Cardiol,2013,162(2):77-85.
[2] Fülster S,Tacke M,Sandek A, et al.Muscle wasting in patients with chronic heart failure:results from the studies investigating comorbidities aggravating heart failure(SICA-HF)[J]. J Eur Heart,2013,34(7):512-519.
[3] Haykowsky MJ,Brubaker PH,Morgan TM,et al.Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass[J]. J Gerontol A Biol Sci Med Sci,2013,68(8):968-975.
[4] Narumi T,Watanabe T,Kadowaki S,et al.Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure[J]. Eur J Intern Med,2015,26(2):118-122.
[5] Cabello-Verrugio C, Córdova G, Salas JD.Angiotensin Ⅱ: role in skeletal muscle atrophy[J]. Curr Protein Pept Sci,2012,13(6):560-569.
[6] Sukhanov S,Semprun-Prieto L,Yoshida T,et al.AngiotensinⅡ,oxidative stress and skeletal muscle wasting[J].Am J Med Sci,2011,342(2):143-147.
[7] Yoshida T,Galvez S,Tiwari S,et al.AngiotensinⅡ inhibits satellite cell proliferation and prevents skeletal muscle regeneration[J]. J Biol Chem,2013,288(33):23823-23832.
[8] Yoshida T, Huq TS, Delafontaine P. Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration[J]. J Biol Chem,2014,289(38):26239-26248.
[9] Elkina Y, von Haehling S, Anker SD, et al.The role of myostatin in muscle wasting:an overview[J]. J Cachexia Sarcopenia Muscle,2011,2(3):143-151.
[10] Heineke J, Auger-Messier M, Xu J,et al.Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure[J].Circulation,2010,121(3):419-425.
[11] Gielen S, Sandri M, Kozarez I,et al.Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig exercise intervention in chronic heart failure and aging catabolism study[J]. Circulation,2012,125(22):2716-2727.
[12] Lenk K, Erbs S, Höllriegel R,et al.Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure[J]. Eur J Cardiovasc Prev Rehabil,2012,19(3):404-411.
[13] Murphy KT,Koopman R,Naim T,et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function[J]. FASEB J,2010,24(11):4433-4442.
[14] Busquets S, Toledo M, Orpí M,et al.Myostatin blockage using actRⅡB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance[J]. J Cachexia Sarcopenia Muscle,2012,3(1):37-43.
[15] Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective[J]. Respir Res, 2001,2(5):269-272.
[16] Schulze PC, Gielen S, Adams V,et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulin like growth factor-I in chronic heart failure[J]. Basic Res Cardiol,2003,98(4):267-274.
[17] Toth MJ, Ades PA, Tischler MD, et al.Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure[J]. Int J Cardiol,2006,109(2):179-187.
[18] Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models[J]. Skeletal Muscle,2011,1(1):4.
[19] Hambrecht R, Schulze PC, Gielen S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure[J]. Eur J Cardiovasc Prev Rehabil,2005,12(4):401-406.
[20] Iellamo F, Volterrani M, Calminti G, et al.Testosterone therapy in women with chronic heart failure. A pilot double-blind, randomized, placebo-controlled study[J]. J Am Coll Cardiol,2015,56(16):1310-1316.
[21] Lima AR, Martinez PF, Okoshi K,et al. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure[J]. Int J Exp Pathol,2010,91(1):54-62.
[22] Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival[J]. Circulation,2006,114(17):1829-1837.
[23] Jankowska EA, Filippatos G, Ponikowska B,et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure[J]. J Card Fail,2009,15(5):442-450.
[24] Cunha TF, Bacurau AV, Moreira JB,et al.Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure[J].PLoS One,2012,7(8):e41701.
[25] Smart NA, Steele M. The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review[J]. Congest Heart Fail, 2011,17(3):110-114.
[26] Hsieh PL, Wu YT, Chao WJ. Effects of exercise training in heart transplant recipients:a meta-analysis[J]. Cardiology,2011,120(1):27-35.
[27] Onder G, Penninx BW, Balkrishnan R,et al.Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women:an observational study[J]. Lancet,2002,359(9310):926-930.
[28] Aquilani R, Opasich C, Gualco A,et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure[J]. Eur J Heart Fail,2008,10(11):1127-1135.
[29] Wandrag L,Brett SJ,Frost G,et al. Impact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness:a systematic review[J]. J Hum Nutr Diet,2015,28(4):313-330.
[30] Caminiti G, Volterrani M, Iellamo F,et al.Effect of long-acting testosterone treatment on functional capacity, skeletal muscle performance, and baroreflex sensitivity in elderly patients with chronic heart failure[J].J Am Coll Cardiol,2009,54(10):919-927.
[31] Palus S, Schur R, Akashi YJ, et al.Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model[J]. PLoS One,2011,6(11):e26865.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[3]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[4]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(3):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[5]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[6]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[7]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(3):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[8]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
[9]李彤 呼海娟 崔炜.慢性心力衰竭患者脑钠肽抵抗机制的研究进展[J].心血管病学进展,2023,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
LI Tong,HU Haijuan,CUI Wei.Mechanism of Brain Natriuretic Peptide Tolerance in Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
[10]高亮 芦颜美.慢性心力衰竭并发肌少症和恶病质的诊治进展[J].心血管病学进展,2023,(7):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]
GAO Liang,LU Yanmei.Diagnosis and Treatment of Chronic Heart Failure Complicated with Sarcopenia and Cachexia[J].Advances in Cardiovascular Diseases,2023,(3):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]